-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HuMNC2-CAR22 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HuMNC2-CAR22 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HuMNC2-CAR22 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HuMNC2-CAR22 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HuMNC2-CAR22 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HuMNC2-CAR22 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC) Drug Details: huMNC2-CAR22 (MUC1*-CAR-1XX)...
-
Product Insights
NewSchizophrenia – Drugs In Development, 2024
Empower your strategies with our Schizophrenia – Drugs In Development, 2024 report and make more profitable business decisions. Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech, and disorganized behavior. Risk factors include family history, age, drugs (psychoactive), and weakened immune system. Treatment includes antipsychotic medications. The Schizophrenia drugs in development market research report provide comprehensive information on the therapeutics under development for Schizophrenia, complete with...
-
Product Insights
Transcatheter Heart Valves Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transcatheter Heart Valves Pipeline Market Report Overview Transcatheter heart valves are synthetic valves made from biological tissues surrounded by a steel, cobalt-chromium, or nitinol stent. These valves can be either balloon-expandable or self-expandable. The Transcatheter Heart Valves pipeline market research report provides comprehensive information about the Transcatheter Heart Valves pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress Key Segments Transcatheter Aortic Valve Replacement (TAVR),...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – huMNC2-CAR44
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry huMNC2-CAR44 Drug Details huMNC2-CAR44 is under development for the treatment of solid tumors such...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
According to the recently published report 'Hepatocyte Growth Factor – Drugs In Development, 2022'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 19 molecules. Out of which approximately 19 molecules are developed by Companies. Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) – Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs...